Lexicon Pharmaceuticals, Inc.
LXRX
$0.53
-$0.0019-0.36%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 47.90% | -21.30% | -10.40% | 2.73% | 1.52% |
| Total Depreciation and Amortization | -0.79% | -9.35% | -3.47% | -2.04% | -2.65% |
| Total Amortization of Deferred Charges | -0.25% | -23.43% | 1.55% | -16.34% | 0.00% |
| Total Other Non-Cash Items | -101.95% | 3,996.00% | -100.61% | 49.85% | 854.39% |
| Change in Net Operating Assets | 21.44% | 128.00% | 137.05% | -168.18% | -154.47% |
| Cash from Operations | 59.92% | -10.46% | 11.95% | -9.06% | -21.45% |
| Capital Expenditure | -54.40% | -22.80% | -- | -- | 100.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 0.74% | 545.42% | 89.05% | -312.39% | 232.25% |
| Cash from Investing | 0.43% | 533.90% | 88.82% | -312.39% | 231.97% |
| Total Debt Issued | -- | -- | -- | -- | -200.00% |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -100.00% | -98.86% | -- | -- |
| Repurchase of Common Stock | -- | -- | 100.00% | -- | 100.00% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -680.00% | 33.33% | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 99.89% | -- | 100.00% | -- | -- |
| Cash from Financing | 88.65% | -6,442.86% | -100.01% | 23,938,400.00% | 99.52% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 3,111.73% | 98.25% | -182.23% | 5,387.69% | 101.66% |